Reply to 'Interleukin-6 in acute heart failure: it does work, but how much'

European Journal of Heart FailureVolume 25, Issue 4 p. 597-598 LETTER TO THE EDITOR Reply to ‘Interleukin-6 in acute heart failure: it does work, but how much?’ Eleni Michou, Eleni Michou orcid.org/0000-0002-1372-1451 Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Basel, SwitzerlandSearch for more papers by this authorDesiree Wussler, Desiree Wussler Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Basel, Switzerland Department of Internal Medicine, University Hospital Basel, Basel, SwitzerlandSearch for more papers by this authorChristian Mueller, Corresponding Author Christian Mueller [email protected] Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Basel, Switzerland Corresponding author. Email: [email protected]Search for more papers by this author Eleni Michou, Eleni Michou orcid.org/0000-0002-1372-1451 Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Basel, SwitzerlandSearch for more papers by this authorDesiree Wussler, Desiree Wussler Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Basel, Switzerland Department of Internal Medicine, University Hospital Basel, Basel, SwitzerlandSearch for more papers by this authorChristian Mueller, Corresponding Author Christian Mueller [email protected] Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Basel, Switzerland Corresponding author. Email: [email protected]Search for more papers by this author First published: 15 February 2023 https://doi.org/10.1002/ejhf.2802Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Michou E, Wussler D, Belkin M, Simmen C, Strebel I, Nowak A, et al. Quantifying inflammation using interleukin-6 for improved phenotyping and risk stratification in acute heart failure. Eur J Heart Fail. 2023. https://doi.org/10.1002/ejhf.2767 2Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, et al.; GALACTIC Investigators. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA. 2019; 322: 2292–302. 3Zannad F, Stein K, Garcia AA, Anker SD, Armstrong PW, Calvo G, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013; 15: 1082–94. 4Wussler D, Du Fay De Lavallaz J, Mueller C. Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med. 2018; 379: 1580. 5Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J. 2006; 151: 845–50. 6Ridker PM. From CRP to IL-6 to IL-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016; 118: 145–56. Volume25, Issue4April 2023Pages 597-598 ReferencesRelatedInformation